INTRODUCTION
■ An estimated 2.7 to 3.9 million Americans suffer from chronic HCV infection. 1 The primary goal of therapy in chronic HCV infection is eradication of HCV RNA, which is predicted by achievement of SVR12. Current treatment guidelines recommend treatment with antiviral medications for all patients with chronic HCV infection. 2 Harvoni ® (ledipasvir/sofosbuvir) is a combination of DAA agents FDA-approved for the treatment of HCV genotypes 1, 4, 5, and 6 on October 10, 2014. 3 ■ Real-world studies of LDV/SOF in the VA system and in academic and community medical centers have shown rates of SVR12 over 90% with 8-week, 12-week, and 24-week courses with and without ribavirin. [4] [5] [6] [7] There is an unmet need for real-world effectiveness data in the Medicaid population.
■ HCV genotype 1 accounts for 74% of chronic HCV infections in the US. 8 › Viral load data was used to calculate the proportion of all members who completed at least one 8-week, 12-week, or 24-week course of LDV/SOF and achieved SVR12.
-Secondary Objectives:
› Viral load data was used to calculate the proportion of members who achieved SVR12 by treatment regimen and by clinical and demographic variables for each treatment regimen.
› The number of members with and without each clinical and demographic variable who achieved SVR12 and who did not achieve SVR12 were used to perform bivariate and multivariate analyses and calculate the odds of failure to achieve SVR12.
DISCUSSION
■ The proportion of members who achieved SVR12 overall is comparable to the proportions of members who achieved SVR12 in other real-world studies of LDV/SOF ( Table 2 ). 4-7 ■ LDV/SOF is FDA-approved as an 8-week regimen in treatment-naïve, non-cirrhotic members with a baseline HCV RNA <6 million IU/mL. 3 Current treatment guidelines note that preliminary real-world data for the comparative effectiveness of 8-week and 12-week regimens in this population is inconclusive, and leave the selection of treatment duration to the discretion of the prescriber. 2 ■ A high proportion of treatment-naïve, non-cirrhotic, HCV mono-infected members with a baseline HCV RNA <6 million IU/mL that received 8 weeks of LDV/SOF achieved SVR12. These results are comparable to those seen with 8-week regimens in other real-world studies of LDV/SOF ( Table 2) . 4-7 ■ The proportion of members who received 12 weeks of LDV/SOF with ribavirin and achieved SVR12 is comparable to the proportion of members who received 24 weeks of LDV/SOF and achieved SVR12 ( Table 2) . ■ Bivariate and multivariate analyses revealed no statistically significant differences in odds of failure to achieve SVR12 by clinical and demographic variables, with the exception of lower odds of failure with cirrhosis in members receiving 24 weeks of treatment.
LIMITATIONS
■ Members for whom viral load data is not available or who had an undetectable viral load less than 12 weeks after treatment completion were not included (N=228). These members may account for additional cure rate data. ■ Pharmacy claims data was only available for claims billed to a MassHealth FFS or PCC plan. Medications billed to other payers or paid in cash are not included, and may account for additional drug-drug interactions. ■ Data regarding history of failure on a previous HCV treatment or DAA agent were compiled from the internal database of the MassHealth comprehensive HCV medication management program, and included discontinuation of prior therapies because of adverse events, as well as relapse after completion of a full treatment course.
CONCLUSION
■ Treatment of HCV genotype 1 with LDV/SOF is associated with a high rate of SVR12 in one state's Medicaid population, including treatment with 8 weeks of LDV/SOF in non-cirrhotic, HCV mono-infected members with a baseline HCV RNA <6 million IU/mL. ■ The clinical and demographic variables included in this study were not found to be predictors of treatment failure, as they were not associated with statistically significant differences in odds of failure to achieve SVR12. However, cirrhosis was associated with lower odds of failure to achieve SVR12 in members receiving 24 weeks of LDV/SOF.
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